trending Market Intelligence /marketintelligence/en/news-insights/trending/voolPxjg1BjsxqfYPEAlug2 content esgSubNav
In This List

Mylan to pay $322M fee if merger with Pfizer's Upjohn unit is terminated

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Mylan to pay $322M fee if merger with Pfizer's Upjohn unit is terminated

Mylan NV would have to pay a $322 million termination fee if its combination with Pfizer Inc.'s Upjohn Inc. unit falls apart under certain conditions.

In case the deal is terminated due to Mylan not being able to obtain approval from its shareholders, the company will reimburse Pfizer for up to $96 million of expenses incurred by the latter in relation to the transaction. This payment will be credited against any termination fee Mylan pays Pfizer.

Meanwhile, if the transaction is terminated, Pfizer is not required to pay Mylan any fee.

In late July, New York-based Pfizer agreed to a combination of its generics and off-patent drugs unit Upjohn with Canonsburg, Pa.-based Mylan to form a new pharmaceutical company called Viatris. The merger, expected to close in the middle of 2020, will create a company estimated to have sales of nearly $20 billion that same year.

Under the all-stock deal, Pfizer shareholders would have a 57% stake in the combined company, while Mylan stockholders would own the remaining 43%.

Viatris will house brands such as erectile dysfunction drug Viagra, cholesterol-lowering therapy Lipitor and the life-saving EpiPen autoinjector for treating severe allergic reactions, as well as several generic HIV medicines.